索拉非尼对中晚期肝细胞肝癌患者近期生活质量影响

Investigation on short-term quality of life in patients with middle-late stage hepatocellular carcinoma treated by sorafenib

目的调查分析口服索拉非尼对中晚期肝细胞肝癌患者近期生活质量的影响。方法运用EORTC生活质量核心量表(EORTC QLQ-C30)对36例口服索拉非尼治疗的患者进行生活质量的调查,分析比较患者治疗前、治疗后一个月生活质量的变化。结果患者服用索拉非尼后1个月EORTC QLQ-C30量表整体生活质量评分下降(P<0.01),在社会功能、躯体功能、情绪功能、角色功能、食欲下降、便秘、腹泻、经济困难方面差异有统计学意义(P<0.05或P<0.01)。结论服用索拉非尼会对患者生活质量产生影响,临床需加强对并发症的观察,采取延续护理干预措施,提供良好的支持系统,从而改善服药后的生活质量。

Objective To investigate the short-term quality of life in patients with middle-late hepatocellular carcinoma treated by sorafenib. Methods The quality of life among 36 cases of pa-tients with oral sorafenib were investigated by questionnaire- C30（ QLQ- C30） V3.0 of EORTC, and the changes in quality of life before and one month after treatment were compared. Results The overall score of EORTC QLQ- C30 in assessment of quality of life was decreased one month after treatment （P 〈0？〇]_）？ Patients received a decreased score in social functioning, physical status, emotion, role functioning, appetite, constipation, diarrhea, and economic difficulties one month after treatment com-pared with those before treatment, with a significant difference （ P 〈 0. 05 or P 〈0.01）. Conclusion The oral administration of sorafenib may affect the short-term quality of life in patients with middle-late hepatocellular carcinoma. It is required to take continuous nursing and set up support system, in order to enhance the patients quality of life.